Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Lipocine Inc.
organization5 mentionslast seen Nov 10, 2026
A biopharmaceutical company developing oral therapeutics using its proprietary drug-delivery technology platform.
Relationships 10
- Lipocine Inc.employsMahesh V. Patel99% confidence5 sources
- Lipocine Inc.developsTLANDO99% confidence2 sources
- Lipocine Inc.developsLPCN 115499% confidence2 sources
- Lipocine Inc.partners withVerity Pharmaceuticals Inc94% confidence1 source
- Lipocine Inc.developsLPCN 110790% confidence1 source
- Lipocine Inc.developsLPCN 114890% confidence1 source
- Lipocine Inc.developsLPCN 240190% confidence1 source
- Lipocine Inc.developsLPCN 220390% confidence1 source
- Lipocine Inc.developsLPCN 220190% confidence1 source
- Lipocine Inc.developsLPCN 210190% confidence1 source
Relationship
Lipocine Inc.developsLPCN 1154
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARNov 10, 2026Lipocine Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that the first participant has been dosed in BLOOM, the Company's Phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression (PPD).
- filingSEC EDGARSep 14, 2026Lipocine Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Lipocine is developing LPCN 1154 as a 48-hour, at-home treatment for PPD